131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma

Status Active, not recruiting

Clinical Trial Summary

This drug is being developed to treat a type of brain cancer, glioma. This study was developed to evaluate the safety, time to disease progression and survival rates after treatment.

Clinical Trial Description

This phase II trial was designed in two sequences. The first sequence, which is now complete to accrual was an open-label, dose escalation, multi-dose study and treated 12 evaluable patients with high-grade glioma.

The second sequence is currently open and accruing eligible subjects with high-grade glioma. The trial is an open-label, randomized study and will accrue a total of 54 evaluable patients. Eligible subjects will be randomized to receive either 3 or 6 injections of 131-I labeled TM-601 (131-I-TM-601), in weekly intervals at the dose determined in the first sequence of the trial. Patients will undergo debulking surgery and placement of a ventricular access device into the tumor cavity for administration of 131I-TM-601. Patients who participated in the first sequence are not eligible to participate in the second sequence of the study.

High-grade gliomas include; glioblastoma multiforme, anaplastic astrocytoma, oligoastrocytoma or gliosarcoma.

Patients will undergo follow-up clinical examinations and magnetic resonance imaging (MRI) assessments, at defined intervals, until 12 months after the first study dose. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00114309
Study type	Interventional
Source	TransMolecular
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	November 2004
Completion date	August 2009

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05023551` - Study of DSP-0390 in Patients With Recurrent High-Grade Glioma	Early Phase 1
Recruiting	`NCT06059690` - Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells	Phase 1/Phase 2
Recruiting	`NCT04116411` - A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients	Phase 2
Terminated	`NCT01902771` - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors	Phase 1
Recruiting	`NCT03175224` - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Phase 2
Completed	`NCT02386826` - INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme	Phase 1
Completed	`NCT00038493` - Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme	Phase 2
Withdrawn	`NCT03980249` - Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells	Early Phase 1
Recruiting	`NCT01923922` - CT Perfusion in the Prognostication of Cerebral High Grade Glioma	N/A
Completed	`NCT01956734` - Virus DNX2401 and Temozolomide in Recurrent Glioblastoma	Phase 1
Completed	`NCT01402063` - PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation	Phase 2
Suspended	`NCT01386710` - Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma	Phase 1/Phase 2
Completed	`NCT01301430` - Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.	Phase 1/Phase 2
Active, not recruiting	`NCT00995007` - A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas	Phase 2
Terminated	`NCT00990496` - A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)	Phase 1
Terminated	`NCT01044966` - A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma	Phase 1/Phase 2
Completed	`NCT00402116` - Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients	Phase 1/Phase 2
Completed	`NCT00112502` - Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme	Phase 2
Completed	`NCT00504660` - 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients	Phase 2
Recruiting	`NCT05366179` - Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc	Phase 1